Arginine-vasopressin (AVP) is a hormone that is essential for both osmotic and cardiovascular homeostasis, and exerts important physiological regulation through three distinct receptors, V1a, V1b, and V2. Although AVP is used clinically as a potent vasoconstrictor (V1a receptor-mediated) in patients with circulatory shock, the physiological role of vasopressin V1a receptors in blood pressure (BP) homeostasis is ill-defined. In this study, we investigated the functional roles of the V1a receptor in cardiovascular homeostasis using gene targeting. The basal BP of conscious mutant mice lacking the V1a receptor gene (V1a ؊/؊ ) was significantly (P < 0.001) lower compared to the wild-type mice (V1a ؉/؉ ) without a notable change in heart rate. There was no significant alteration in cardiac functions as assessed by echocardiogram in the mutant mice. AVP-induced vasopressor responses were abolished in the mutant mice; rather, AVP caused a decrease in BP, which occurred in part through V2 receptor-mediated release of nitric oxide from the vascular endothelium. Arterial baroreceptor reflexes were markedly impaired in mutant mice, consistent with a loss of V1a receptors in the central area of baroreflex control. Notably, mutant mice showed a significant 9% reduction in circulating blood volume. Furthermore, mutant mice had normal plasma AVP levels and a normal AVP secretory response, but had significantly lower adrenocortical responsiveness to adrenocorticotropic hormone. Taken together, these results indicate that the V1a receptor plays an important role in normal resting arterial BP regulation mainly by its regulation of circulating blood volume and baroreflex sensitivity.knockout mouse ͉ adrenal cortex T he neurohypophyseal hormone arginine vasopressin (AVP) is involved in a plethora of physiological regulatory processes that occur via stimulation of specific V1a, V1b, and V2 receptors (1). These receptors have distinct pharmacological profiles and couple with specific intracellular second messengers (1). Vasopressin plays a prominent role in the cardiovascular system and influences arterial blood pressure (BP) at multiple sites in a complex fashion. The role of AVP has been well characterized in the regulation of BP in pathophysiological conditions such as severe hypovolemia͞hypotension episodes (2). However, its contribution to BP homeostasis in normal physiological situations is ill-defined (3). Vasopressin is a potent stimulator of vascular smooth muscle contraction in vitro, and V1a receptors mediate its vasoconstrictor effect (3). However, a relatively large amount of vasopressin is required to raise BP in vivo under normal physiological conditions (4); this is thought to be because vasopressin also acts on the brain, decreasing cardiac output by inhibiting sympathetic efferent activity and potentiating baroreflexes (5). AVP has been shown to enhance baroreflex function via activation of V1 receptors in the area postrema (6-8). In addition, vasopressin causes vasodilatation in some blood vessels, perhaps via rele...
(62)Cu-ATSM PET imaging demonstrated increased oxidative stress based on an over-reductive state, primarily in the motor cortex, in patients with ALS. The magnitude of oxidative stress correlated well with clinical severity, indicating that it may be associated with neurodegenerative changes in ALS.
Nitrogen containing-bisphosphonates (N-BPs), widely used to treat bone diseases, have direct antitumor effects via the inactivation of Ras proteins. In addition to the direct antitumor activities, N-BPs expand gdT cells, which exhibit major histocompatibility complex-unrestricted lytic activity. BPs accumulate intermediate metabolites which may be tumor antigens in target cells. The purpose of our study was to clarify the cytotoxicity of gd T cells expanded ex vivo by the most potent N-BP, zoledronate (ZOL). Especially, we focused on the importance of pretreatment against target cells also with ZOL; 1 mM ZOL plus IL-2 increased the absolute number of gdT cells 298-768 fold for 14 days incubation. The small cell lung cancer and fibrosarcoma cell lines pretreated with 5 mM ZOL showed a marked increase in sensitivity to lysis by gdT cells. While, untreated cell lines were much less sensitive to lysis by gdT cells. Video microscopy clearly demonstrated that gdT cells killed target cells pre-treated with ZOL within 3 hr. Pretreatment with 80 mg/kg ZOL also significantly enhanced the antitumor activity of gdT cells in mice xenografted with SBC-5 cells. These findings show that ZOL significantly stimulated the proliferation of gdT cells and that gdT cells required pre-treatment with ZOL for cytotoxic activity against target cells. ' 2005 Wiley-Liss, Inc.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.